Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTN-026: Rectal Dapivirine Gel Safety/PK
NCT03239483Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Dapivirine gel with Placebo gel (2 arms). Primary endpoints: Frequency of Grade 2 or Higher Adverse Events at Day 40, Dapivirine Concentrations in Plasma at 72 hours and 3 more. Started Oct 2017; status: completed.
02
Drugs
dapivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03239483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239483.